Avance Clinical Guides 710 Emerging Biotechs Through Critical Early-Phase Milestones

28 August 2025 | Thursday | News


By accelerating timelines by up to nine months and addressing common operational hurdles, Avance Clinical enables biotechs to secure funding, advance to Phase II, and progress pivotal studies with greater confidence.
Image Source : Public Domain

Image Source : Public Domain

Avance Clinical, a partner for biotechs providing global contract research organization services, has now guided 710 emerging biotechs through critical clinical trial inflection points.

Avance Clinical’s comprehensive approach to Phase I clinical development has delivered consistent results across the portfolio, bridging studies and first-in-human trials. Most of these programs have successfully advanced to their next milestone, including securing follow-on funding, progressing to Phase II trials, and initiating more pivotal studies.

“Too often biotechs stall, not because of science, but because they are unable to navigate early-phase inflection points efficiently,” said Mark Harvill, CEO, at Avance Clinical. “Much like a start-up benefits from a solid foundation, we’re creating the acceleration for emerging biotechs to help them get to those critical milestones. By accelerating timelines by as much as nine months, we’re advancing their progress and potentially delivering life-changing treatments to patients sooner.”

Those common hurdles which stall early-stage biotechs are largely due to strategic or operational misalignment. Most often, biotechs experience this in:

  • Delayed toxicology data, which can postpone regulatory submission
  • Funding gaps, which slow the start of a study or progression to the next phase
  • Internal hiring delays, which can leave a client under resourced during critical phases
  • Lack of strategic planning, which allows teams to anticipate potential bottlenecks before they occur

Avance Clinical addresses these challenges proactively by assessing early data and preparing regulatory submissions up front. This approach ensures clients can anticipate roadblocks, reduce delays, protect capital from the beginning, and overall provide greater confidence to reach their next inflection point.

“These achievements highlight the strategic value of integrating operational excellence with expert regulatory guidance to de-risk early-stage development,” said Ben Edwards, Chief Operating Officer, at Avance Clinical. “This direction allows us to be the accelerator for our clients to ensure a sustained competitive advantage and progression through later stage development.”

News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close